Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNTX NASDAQ:NKTX NASDAQ:PDSB NASDAQ:SLGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTXContext Therapeutics$2.46+2.7%$2.62$0.49▼$3.62$224.19M1.571.35 million shs56,259 shsNKTXNkarta$3.21+0.8%$2.56$1.63▼$3.65$226.35M0.88816,880 shs64,869 shsPDSBPDS Biotechnology$1.13-13.5%$0.86$0.51▼$1.92$61.20M1.51751,424 shs749,432 shsSLGLSol-Gel Technologies$68.35-2.3%$77.75$6.80▼$97.97$187.68M1.1634,438 shs5,881 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTXContext Therapeutics+0.42%+5.29%-4.02%+1.27%+213.85%NKTXNkarta-0.31%+8.53%+46.54%+59.00%+63.50%PDSBPDS Biotechnology+4.00%+32.56%+20.37%+83.10%+9.13%SLGLSol-Gel Technologies-1.24%-7.45%-6.52%+7.66%+791.46%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTXContext Therapeutics$2.46+2.7%$2.62$0.49▼$3.62$224.19M1.571.35 million shs56,259 shsNKTXNkarta$3.21+0.8%$2.56$1.63▼$3.65$226.35M0.88816,880 shs64,869 shsPDSBPDS Biotechnology$1.13-13.5%$0.86$0.51▼$1.92$61.20M1.51751,424 shs749,432 shsSLGLSol-Gel Technologies$68.35-2.3%$77.75$6.80▼$97.97$187.68M1.1634,438 shs5,881 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTXContext Therapeutics+0.42%+5.29%-4.02%+1.27%+213.85%NKTXNkarta-0.31%+8.53%+46.54%+59.00%+63.50%PDSBPDS Biotechnology+4.00%+32.56%+20.37%+83.10%+9.13%SLGLSol-Gel Technologies-1.24%-7.45%-6.52%+7.66%+791.46%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTXContext Therapeutics 2.88Moderate Buy$6.60168.84% UpsideNKTXNkarta 2.40Hold$11.33253.50% UpsidePDSBPDS Biotechnology 2.33Hold$9.00700.00% UpsideSLGLSol-Gel Technologies 2.33Hold$110.0060.95% UpsideCurrent Analyst Ratings BreakdownLatest PDSB, SLGL, NKTX, and CNTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2026SLGLSol-Gel Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)4/21/2026PDSBPDS Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026CNTXContext Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/15/2026PDSBPDS Biotechnology HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.003/31/2026NKTXNkarta MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$14.00 ➝ $12.003/27/2026NKTXNkarta Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/26/2026NKTXNkarta Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $11.003/24/2026CNTXContext Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.003/24/2026CNTXContext Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.003/24/2026CNTXContext Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$4.00 ➝ $7.002/23/2026CNTXContext Therapeutics Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTXContext TherapeuticsN/AN/AN/AN/A$0.66 per shareN/ANKTXNkartaN/AN/AN/AN/A$4.40 per shareN/APDSBPDS BiotechnologyN/AN/AN/AN/A$0.18 per shareN/ASLGLSol-Gel Technologies$19.39M9.90N/AN/A$8.19 per share8.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTXContext Therapeutics-$36.12M-$0.42N/AN/AN/AN/A-59.95%-54.78%N/ANKTXNkarta-$104.08M-$1.40N/AN/AN/AN/A-30.02%-23.78%5/13/2026 (Estimated)PDSBPDS Biotechnology-$34.50M-$0.75N/AN/AN/AN/A-241.95%-90.36%5/13/2026 (Estimated)SLGLSol-Gel Technologies-$6.13M-$2.23N/AN/AN/A-31.60%-24.29%-18.73%5/22/2026 (Estimated)Latest PDSB, SLGL, NKTX, and CNTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2026Q1 2026SLGLSol-Gel Technologies-$1.84N/AN/AN/A$0.90 millionN/A5/13/2026Q1 2026NKTXNkarta-$0.39N/AN/AN/AN/AN/A5/13/2026Q1 2026PDSBPDS Biotechnology-$0.15N/AN/AN/AN/AN/A5/6/2026Q1 2026CNTXContext Therapeutics-$0.12-$0.09+$0.03-$0.09N/AN/A3/30/2026Q4 2025PDSBPDS Biotechnology-$0.20-$0.14+$0.06-$0.14N/AN/A3/25/2026Q4 2025NKTXNkarta-$0.32-$0.37-$0.05-$0.37N/AN/A3/23/2026Q4 2025CNTXContext Therapeutics-$0.11-$0.14-$0.03-$0.14N/AN/A3/19/2026Q4 2025SLGLSol-Gel Technologies$0.39-$1.07-$1.46-$1.06$6.50 million$0.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCNTXContext TherapeuticsN/AN/AN/AN/AN/ANKTXNkartaN/AN/AN/AN/AN/APDSBPDS BiotechnologyN/AN/AN/AN/AN/ASLGLSol-Gel TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTXContext TherapeuticsN/A8.968.96NKTXNkartaN/A12.6912.69PDSBPDS Biotechnology1.272.982.98SLGLSol-Gel TechnologiesN/A4.374.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTXContext Therapeutics14.03%NKTXNkarta80.54%PDSBPDS Biotechnology26.84%SLGLSol-Gel Technologies26.18%Insider OwnershipCompanyInsider OwnershipCNTXContext Therapeutics4.80%NKTXNkarta8.40%PDSBPDS Biotechnology9.20%SLGLSol-Gel Technologies66.51%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNTXContext Therapeutics791.88 million87.47 millionNot OptionableNKTXNkarta14071.29 million65.30 millionOptionablePDSBPDS Biotechnology2054.40 million49.40 millionOptionableSLGLSol-Gel Technologies502.81 million941,000No DataPDSB, SLGL, NKTX, and CNTX HeadlinesRecent News About These CompaniesSol-Gel Technologies Ltd. (NASDAQ:SLGL) Short Interest Up 48.9% in AprilApril 28, 2026 | marketbeat.comSol-Gel Technologies Ltd. (NASDAQ:SLGL) Short Interest Down 31.7% in MarchApril 14, 2026 | marketbeat.comSol-Gel Technologies (NASDAQ:SLGL) Shares Down 0.6% - Time to Sell?April 14, 2026 | marketbeat.comSol-Gel Technologies Ltd. Announces Pricing of $33.1 Million Underwritten Offering of Ordinary SharesMarch 23, 2026 | quiverquant.comQSol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten OfferingMarch 23, 2026 | globenewswire.comSol-Gel Technologies Ltd. (SLGL) Reports Q4 Loss, Misses Revenue EstimatesMarch 19, 2026 | zacks.comSol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025March 19, 2026 | globenewswire.comThis Under-the-Radar Stock Has Surged 1,300% Over the Past YearMarch 13, 2026 | finance.yahoo.comSol-Gel Technologies (NASDAQ:SLGL) shareholders have earned a 940% return over the last yearFebruary 11, 2026 | finance.yahoo.comSol-Gel Technologies (SLGL) price target increased by 120.00% to 112.20February 4, 2026 | msn.comOpaleye Management Inc. Buys 1,151 Shares of Sol-Gel Technologies (NASDAQ:SLGL) StockJanuary 24, 2026 | insidertrades.comSol-Gel Technologies: Downgrading To 'Hold' As Success Relies On Upcoming Q4 CatalystJanuary 18, 2026 | seekingalpha.comSol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Opaleye Management Inc. Acquires 8,638 SharesJanuary 1, 2026 | insidertrades.comInsider Buying: Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Purchases $10,831.60 in StockDecember 30, 2025 | insidertrades.comWe Think Sol-Gel Technologies (NASDAQ:SLGL) Can Easily Afford To Drive Business GrowthDecember 29, 2025 | finance.yahoo.comWhy Sol-Gel Technologies Ltd.’s (SLGL) Stock Is Down 5.05%December 27, 2025 | aaii.comASol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Opaleye Management Inc. Buys 2,735 SharesDecember 20, 2025 | insidertrades.comSol-Gel Technologies updates clinical pipeline following Phase 1b resultsDecember 17, 2025 | msn.comSol-Gel halts studies for rare disease therapy after trial setbackDecember 17, 2025 | msn.comSol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier DiseaseDecember 17, 2025 | markets.businessinsider.comSol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Purchases $95,432.44 in StockDecember 4, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePDSB, SLGL, NKTX, and CNTX Company DescriptionsContext Therapeutics NASDAQ:CNTX$2.46 +0.07 (+2.72%) As of 11:11 AM Eastern This is a fair market value price provided by Massive. Learn more.Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.Nkarta NASDAQ:NKTX$3.21 +0.03 (+0.82%) As of 11:10 AM Eastern This is a fair market value price provided by Massive. Learn more.Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.PDS Biotechnology NASDAQ:PDSB$1.12 -0.18 (-13.46%) As of 11:09 AM Eastern This is a fair market value price provided by Massive. Learn more.PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.Sol-Gel Technologies NASDAQ:SLGL$68.35 -1.63 (-2.33%) As of 11:10 AM Eastern This is a fair market value price provided by Massive. Learn more.Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
